BusinessSummit Completes Dosing of Ezutromid in PhaseOut DMD Clinical TrialBy Nasdaq OMXApr 19, 2018, 11:01 AM UTC
BusinessSummit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMDBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
BusinessEzutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical TrialBy Nasdaq OMXJan 25, 2018, 12:01 PM UTC
BusinessSanthera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness DayBy Nasdaq OMXDec 6, 2017, 7:00 AM UTC
BusinessSummit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialBy Nasdaq OMXNov 20, 2017, 12:00 PM UTC
BusinessSummit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ConferenceBy Nasdaq OMXNov 9, 2017, 12:01 PM UTC
BusinessSummit Highlights DMD Biomarker Validation Data and Phase 2 Clinical Trial Baseline Characteristics in Presentations at 22nd WMS CongressBy Nasdaq OMXOct 4, 2017, 11:00 AM UTC
BusinessSummit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular DystrophyBy Nasdaq OMXSep 25, 2017, 11:00 AM UTC
